1393125-75-1

Upstream product

• 34970-21-3 3,3-dimethylcyclobutane-1-carbonyl chloride 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 34970-18-8 3,3-dimethylcyclobutanecarboxylic acid 

Downstream Products

• 1393126-14-1 ethyl 4-((3,3-dimethylcyclobutyl)(hydroxy)methyl)benzoate 
• 1393126-15-2 ethyl 3-(4-(3,3-dimethylcyclobutanecarbonyl)benzamido)propanoate 
• 1393126-16-3 4-(3,3-dimethylcyclobutanecarbonyl)benzoic acid 
• 1393126-17-4 ethyl 3-(4-((3,3-dimethylcyclobutyl)(hydroxy)methyl)benzamido)propanoate 
• 1393124-81-6 (+/-)-3-(4-((3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)(3,3-dimethylcyclobutyl)methyl)benzamido)propanoic acid 
• 1393127-56-4 ethyl 4-((3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)(3,3-dimethylcyclobutyl)methyl)benzoate 
• 1393127-58-6 ethyl 3-(4-((3,5-dimethyl-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)phenoxy)(3,3-dimethylcyclobutyl)methyl)benzamido)propanoate 
• 1421348-87-9 C₂₅H₂₆N₂O₂ 
• 1421348-49-3 C₂₆H₂₈FN₃O₃ 
• 1421348-50-6 C₂₆H₂₈FN₃O₃ 
• 1421348-51-7 C₂₆H₂₉N₃O₃ 
• 1421348-73-3 (+/-)-4-[amino-(3,3-dimethyl-cyclobutyl)-methyl]-benzoic acid ethyl ester 
• 1421348-74-4 (+/-)-4-[(3,3-dimethyl-cyclobutyl)-(3-methyl-quinolin-2-ylamino)-methyl]-benzoic acid ethyl ester 
• 1421348-75-5 (+/-)-4-[(3,3-dimethyl-cyclobutyl)-(3-methyl-quinolin-2-ylamino)-methyl]-benzoic acid 

Relevant academic research and scientific papers

QUINOLINYL GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

GLUCAGON RECEPTOR MODULATORS

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.